key: cord-0870781-6ol3iql1
authors: Abou‐Ismail, Mouhamed Yazan; Moser, Karen A.; Smock, Kristi J.; Lim, Ming Y.
title: Vaccine‐induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism
date: 2021-06-17
journal: Am J Hematol
DOI: 10.1002/ajh.26265
sha: 499d47386be6bf3478dfcf106216fdb0270a8d29
doc_id: 870781
cord_uid: 6ol3iql1

nan

Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism

To the Editor:

The emergent need to combat the coronavirus disease 2019 pandemic led to the development of several highly effective vaccines at unprecedented speeds, using highly advanced technology and scientific research. The initial trials demonstrated the safety of these vaccines, and the risk of serious adverse effects remains significantly low even after the vaccination of more than 1.5 billion people worldwide to date. The Ad26. In March 2021, a rare, life-threatening syndrome was first described by the European Medicines Agency as thrombotic thrombocytopenic syndrome (TTS) following ChAdOx1 nCoV-19 vaccination (AstraZeneca), a recombinant replication-deficient chimpanzee adenovirus vector. 1 The syndrome, now recognized as vaccineinduced thrombotic thrombocytopenia (VITT), results in pathologic anti-platelet factor 4 (PF4) antibodies leading to thrombocytopenia and thrombosis in the absence of heparin exposure, a mechanism similar to "autoimmune" heparin-induced thrombocytopenia (HIT). 2, 3 On April 13th, 2021, six cases of VITT were reported in the United States following vaccination by the Ad26.COV2.S vaccine, all of whom were women who developed cerebral venous sinus thrombosis (CVST). 4 This led to an 11-day pause in the administration of the vaccine, during which a thorough investigation led to its resumption by the Centers for Disease Control (CDC) and FDA, but revised to include a warning about this rare side effect. By April 27th, 2021, the number of VITT cases following Ad26.COV2. S vaccination reported in the US had risen to 15, all of whom were women of ages 20 to 50 years, and included 12 incidences of CVST. 5, 6 To date, the only report of suspected VITT in a male Ad26.COV2.S vaccine recipient in the medical literature comes from the initial Johnson & Johnson phase 3 trials. One of the male trial participants who developed CVST, thrombocytopenia, and positive anti-PF4 antibodies is suspected to have had VITT, but additional details have not been provided. 7 We hereby report the case of a man with confirmed VITT following Ad26.COV2.S vaccination, resulting in acute deep venous thrombosis (DVT) and bilateral pulmonary emboli (PE), and a post-discharge course complicated by refractory thrombocytopenia. Figure 1) , however, the SRA was no longer positive. Within a week post-discharge, he developed recurrent thrombocytopenia, with a platelet count that down trended to 107 Â 10 9 /L ( Figure 1 ). His thrombocytopenia appeared to somewhat correlate with prednisone dose adjustments, suggesting an autoimmune-driven process, although it did not respond to repeat IVIG administration. Due to the normalized D-Dimer levels and negative SRA, it was assumed that there was no further ongoing platelet activation.

To the best of our knowledge, this is the first published case in the medical literature describing a confirmed VITT diagnosis affecting a male Ad26.COV2.S vaccine recipient since the vaccine's authorization. This is also the first case describing the post-discharge course.

At the time of this report, the most recent update by the CDC describes a total of six men in the US affected by TTS (our patient included), with a 78% female predominance. 8 The most recent data from the UK also shows a female predominance in VITT following ChAdOx1 nCoV-19 vaccination. 9 Furthermore, the majority of cases of VITT described to date appear to occur in unusual locations, namely CVST in 19 out of the recently reported 28 cases of VITT in the US, as well as a majority of the cases reported in Europe following ChAdOx1 nCoV-19 vaccine. 10 disorder. In our case, the patient developed refractory thrombocytopenia which we believe is immune-mediated, but not associated with further platelet activation. Refractory thrombocytopenia may pose a bleeding risk for patients on therapeutic anticoagulation, and guidelines on the optimal management of this phenomenon are urgently needed. Importantly, we emphasize the need for early recognition of VITT syndrome by physicians, as underrecognition may lead to increased morbidity and mortality, whereas early recognition may permit rapid treatment and improvement of symptoms, as seen in our case. 

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Mouhamed Yazan Abou-Ismail 1 , Karen A. Moser 2,3 , Kristi

COVID-19 vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia

Cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson & Johnson COVID-19 vaccine

Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients-United States

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26

Thrombotic thrombocytopenia after Ad26.COV2.S vaccination-response from the manufacturer

Update: thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination

Coronavirus vaccine -weekly summary of Yellow Card reporting. Medicines & Healthcare Products Regulatory Agency

Vaccine-induced immune thrombocytopenia and thrombosis (VITT)

Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination

Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination

Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH